Published: 4 December 2025
Publications
MARC’s remarks: September 2025 meeting
Published: 4 December 2025
Prescriber Update 46(4): 62
December 2025
The Medicines Adverse Reaction Committee (MARC) convened for their 203rd meeting on 11 September 2025.
The Committee reviewed the potential interaction between glucagon-like peptide-1 (GLP-1) receptor agonists, such as dulaglutide, liraglutide and semaglutide, with oral contraceptives. The Committee considered that there was insufficient evidence at this time to support updates to the data sheets.
The risk of intestinal angioedema with angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) was discussed. The Committee considered that intestinal angioedema may be a less well recognised manifestation of angioedema due to its non-specific presentation. They recommended data sheet updates to include information about intestinal angioedema. See also the article about intestinal angioedema in this edition of Prescriber Update.
The Committee reviewed the risk of seizures in patients with convulsive disorders using beta-2 agonists. They determined there was insufficient evidence to support a causal association. The Committee noted that the data sheets of specific beta-2 agonist containing medicines currently containing seizure-related information. The Committee asked Medsafe to review this data to ensure there is consistent information across the beta-2 agonist data sheets.
See the Medsafe website for the MARC meeting minutes and the reports presented to the MARC.
